Synairgen plc (SYGGF)
USD 0.04
(-23.64%)
USD 0.04
(-23.64%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -10.2 Million GBP | 48.94% |
| 2022 | -19.99 Million GBP | 65.33% |
| 2021 | -57.66 Million GBP | -230.2% |
| 2020 | -17.46 Million GBP | -277.64% |
| 2019 | -4.62 Million GBP | -13.0% |
| 2018 | -4.09 Million GBP | -349.66% |
| 2017 | 1.63 Million GBP | 148.01% |
| 2016 | -3.41 Million GBP | -32.43% |
| 2015 | -2.57 Million GBP | -325.94% |
| 2014 | 1.14 Million GBP | 151.49% |
| 2013 | -2.21 Million GBP | 8.2% |
| 2012 | -2.41 Million GBP | 32.94% |
| 2011 | -3.6 Million GBP | -25.83% |
| 2010 | -3.63 Million GBP | -4.65% |
| 2009 | -2.93 Million GBP | -14.73% |
| 2008 | -2.73 Million GBP | -31.51% |
| 2007 | -1.81 Million GBP | -44.27% |
| 2006 | -1.81 Million GBP | -118.06% |
| 2005 | -1.63 Million GBP | -281.46% |
| 2004 | -874 Thousand GBP | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q2 | -5.46 Million GBP | -199900.0% |
| 2023 Q1 | -2732.00 GBP | 99.96% |
| 2023 FY | - GBP | 48.94% |
| 2023 Q4 | -2372.00 GBP | 0.0% |
| 2023 Q3 | -2372.00 GBP | 99.96% |
| 2022 Q1 | -6978.50 GBP | 99.96% |
| 2022 FY | - GBP | 65.33% |
| 2022 Q4 | -6.24 Million GBP | -199900.0% |
| 2022 Q3 | -3120.50 GBP | 99.98% |
| 2022 Q2 | -13.95 Million GBP | -199900.0% |
| 2021 Q3 | -9459.00 GBP | 99.98% |
| 2021 Q1 | -19.42 Thousand GBP | 99.85% |
| 2021 FY | - GBP | -230.2% |
| 2021 Q2 | -38.76 Million GBP | -199482.98% |
| 2021 Q4 | -18.9 Million GBP | -199762.56% |
| 2020 Q3 | -6308.00 GBP | 99.87% |
| 2020 Q2 | -4.94 Million GBP | -196676.76% |
| 2020 Q1 | -2513.00 GBP | 99.9% |
| 2020 Q4 | -12.53 Million GBP | -198631.77% |
| 2020 FY | - GBP | -277.64% |
| 2019 Q1 | -1079.00 GBP | 3.62% |
| 2019 Q3 | -1281.50 GBP | 99.94% |
| 2019 FY | - GBP | -13.0% |
| 2019 Q4 | -2.49 Million GBP | -194671.75% |
| 2019 Q2 | -2.15 Million GBP | -199900.0% |
| 2018 Q3 | -1119.50 GBP | -20.83% |
| 2018 Q1 | -926.50 GBP | -157.87% |
| 2018 FY | - GBP | -349.66% |
| 2018 Q2 | -926.50 GBP | 0.0% |
| 2018 Q4 | -1119.50 GBP | 0.0% |
| 2017 Q3 | 1601.00 GBP | 304.86% |
| 2017 FY | - GBP | 148.01% |
| 2017 Q4 | 1601.00 GBP | 0.0% |
| 2017 Q1 | -781.50 GBP | 10.28% |
| 2017 Q2 | -781.50 GBP | 0.0% |
| 2016 FY | - GBP | -32.43% |
| 2016 Q2 | -836.00 GBP | 0.0% |
| 2016 Q4 | -871.00 GBP | 0.0% |
| 2016 Q1 | -836.00 GBP | -7.46% |
| 2016 Q3 | -871.00 GBP | -4.19% |
| 2015 Q4 | -778.00 GBP | 0.0% |
| 2015 FY | - GBP | -325.94% |
| 2015 Q3 | -778.00 GBP | -52.25% |
| 2015 Q2 | -511.00 GBP | 0.0% |
| 2015 Q1 | -511.00 GBP | -31.87% |
| 2014 Q2 | 958.00 GBP | 0.0% |
| 2014 Q1 | 958.00 GBP | 282.65% |
| 2014 Q4 | -387.50 GBP | 0.0% |
| 2014 FY | - GBP | 151.49% |
| 2014 Q3 | -387.50 GBP | -140.45% |
| 2013 Q3 | -524.50 GBP | 10.11% |
| 2013 Q1 | -583.50 GBP | 0.0% |
| 2013 Q4 | -524.50 GBP | 0.0% |
| 2013 Q2 | -583.50 GBP | 0.0% |
| 2013 FY | - GBP | 8.2% |
| 2012 FY | - GBP | 32.94% |
| 2011 FY | - GBP | -25.83% |
| 2010 FY | - GBP | -4.65% |
| 2009 FY | - GBP | -14.73% |
| 2008 FY | - GBP | -31.51% |
| 2007 FY | - GBP | -44.27% |
| 2006 FY | - GBP | -118.06% |
| 2005 FY | - GBP | -281.46% |
| 2004 FY | - GBP | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -628.202% |
| CSL Limited | 4.78 Billion USD | 100.213% |
| Eiger BioPharmaceuticals, Inc. | -71.03 Million USD | 85.63% |
| Nanobac Pharmaceuticals, Incorporated | -5.92 Million USD | -72.173% |
| Institute of Biomedical Research Corp. | -239.15 Thousand USD | -4168.451% |
| Evofem Biosciences, Inc. | -17.37 Million USD | 41.232% |
| Santhera Pharmaceuticals Holding AG | 94.03 Million USD | 110.855% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -564.562% |
| Mesoblast Limited | -62.38 Million USD | 83.638% |
| Marizyme, Inc. | -34.28 Million USD | 70.223% |
| Genus plc | 73.7 Million USD | 113.851% |
| VioQuest Pharmaceuticals, Inc. | -6.61 Million USD | -54.397% |
| CNBX Pharmaceuticals Inc. | -3.54 Million USD | -187.793% |
| Nymox Pharmaceutical Corporation | -8.77 Million USD | -16.37% |
| ContraFect Corporation | -64.99 Million USD | 84.295% |
| PsyBio Therapeutics Corp. | -4.52 Million USD | -125.532% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| IMV Inc. | -35.52 Million USD | 71.264% |
| AXIM Biotechnologies, Inc. | -2.32 Million USD | -339.277% |
| MultiCell Technologies, Inc. | -518.04 Thousand USD | -1870.481% |
| Accustem Sciences Inc. | -3.74 Million USD | -172.474% |
| RVL Pharmaceuticals plc | -48.22 Million USD | 78.833% |
| EV Biologics, Inc. | -1.26 Million USD | -705.599% |
| Q BioMed Inc. | -617.62 Thousand USD | -1552.775% |
| Emmaus Life Sciences, Inc. | 3.57 Million USD | 385.778% |
| Mosaic ImmunoEngineering Inc. | -2.28 Million USD | -346.84% |
| Biomind Labs Inc. | -1.03 Million USD | -886.71% |
| Oncotelic Therapeutics, Inc. | -7.16 Million USD | -42.544% |
| Skye Bioscience, Inc. | -13.54 Million USD | 24.651% |
| SQZ Biotechnologies Company | -64.14 Million USD | 84.085% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | -40732.0% |
| Arch Therapeutics, Inc. | -3.88 Million USD | -162.8% |
| Intellipharmaceutics International Inc. | -2.64 Million USD | -286.016% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 35.676% |
| Neon Bloom, Inc. | -632.4 Thousand USD | -1514.153% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 9.87 Million USD | 203.351% |
| Therapeutic Solutions International, Inc. | -1.48 Million USD | -586.293% |
| Curative Biotechnology, Inc. | -2.5 Million USD | -308.0% |
| GB Sciences, Inc. | -1.41 Million USD | -618.931% |
| Alpha Cognition Inc. | -9.7 Million USD | -5.176% |
| argenx SE | -216.02 Million USD | 95.275% |
| HST Global, Inc. | -5303.00 USD | -192394.814% |
| Halberd Corporation | -74.27 Thousand USD | -13642.781% |
| Enzolytics Inc. | -2.12 Million USD | -381.049% |
| Resverlogix Corp. | -11.74 Million USD | 13.064% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| Nuo Therapeutics, Inc. | -3.06 Million USD | -233.266% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.33 Million USD | 81.554% |
| American Oriental Bioengineering, Inc. | -39.63 Million USD | 74.246% |
| Enzon Pharmaceuticals, Inc. | 1.21 Million USD | 938.784% |
| Provectus Biopharmaceuticals, Inc. | -2.89 Million USD | -252.934% |
| Endonovo Therapeutics, Inc. | 8.85 Million USD | 215.295% |
| GlobeStar Therapeutics Corporation | 6724.00 USD | 151914.396% |
| RespireRx Pharmaceuticals Inc. | -1.49 Million USD | -581.03% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | 378.84 Thousand USD | 2794.513% |
| AVAX Technologies, Inc. | -6.11 Million USD | -66.998% |
| ONE Bio Corp. | 13.61 Million USD | 174.987% |
| Zenith Capital Corp. | -8.6 Million USD | -18.615% |
| Genscript Biotech Corporation | -248.71 Million USD | 95.896% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -58495.947% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.44 Million USD | -317.256% |
| WPD Pharmaceuticals Inc. | -176.02 Thousand USD | -5699.197% |
| Cotinga Pharmaceuticals Inc. | -1.92 Million USD | -431.415% |
| Wesana Health Holdings Inc. | -2.05 Million USD | -396.257% |
| Agentix Corp. | -1.37 Million USD | -644.156% |
| Adynxx, Inc. | - USD | Infinity% |
| Kadimastem Ltd | -2.62 Million USD | -288.968% |
| Helix BioMedix, Inc. | -1.04 Million USD | -875.617% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.74 Million USD | -483.315% |
| BioStem Technologies, Inc. | -7.55 Million USD | -35.14% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.08 Thousand USD | -5537.038% |
| Burzynski Research Institute, Inc. | - USD | Infinity% |
| LadRx Corporation | 412.28 Thousand USD | 2575.969% |
| Cell Source, Inc. | -4.27 Million USD | -138.922% |
| ProtoKinetix, Incorporated | -367.22 Thousand USD | -2679.797% |
| Regen BioPharma, Inc. | 1.46 Million USD | 796.337% |
| Regen BioPharma, Inc. | -936.94 Thousand USD | -989.494% |
| NovAccess Global Inc. | -1.03 Million USD | -886.474% |
| Affymax, Inc. | -14.29 Million USD | 28.59% |
| Itoco Inc. | -1.86 Million USD | -446.176% |
| Rasna Therapeutics, Inc. | -379.62 Thousand USD | -2589.005% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -814.695% |
| CytoDyn Inc. | -18.02 Million USD | 43.38% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -79.02 Thousand USD | -12816.777% |
| NanoSphere Health Sciences Inc. | -12.22 Thousand USD | -83373.71% |
| Qrons Inc. | -40.08 Thousand USD | -25368.426% |
| Alseres Pharmaceuticals, Inc. | -485.67 Thousand USD | -2001.804% |
| SYBLEU INC | -141.57 Thousand USD | -7110.516% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | 527.43 Thousand USD | 2035.412% |
| Rebus Holdings, Inc. | -951 Thousand USD | -973.396% |
| ImmunoCellular Therapeutics, Ltd. | -1.06 Million USD | -861.196% |
| Mobile Lads Corp. | -2.24 Million USD | -355.479% |
| International Stem Cell Corporation | 202 Thousand USD | 5153.465% |
| Bioxytran, Inc. | -3.82 Million USD | -167.215% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -19292.097% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -2.46 Million USD | -314.634% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -35.86 Million USD | 71.541% |
| Adhera Therapeutics, Inc. | - USD | Infinity% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -45 Thousand USD | -22584.444% |
| Innovation Pharmaceuticals Inc. | -2.73 Million USD | -272.827% |
| Neutra Corp. | -181.24 Thousand USD | -5532.093% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 49.363% |
| PureTech Health plc | -11.62 Million USD | 12.204% |
| Coeptis Therapeutics, Inc. | -20.15 Million USD | 49.359% |
| IXICO plc | -707 Thousand USD | -1343.847% |
| IntelGenx Technologies Corp. | -7.68 Million USD | -32.83% |
| Gelesis Holdings, Inc. | -48.34 Million USD | 78.886% |
| CSL Limited | 4.73 Billion USD | 100.216% |
| Cellectis S.A. | -92.63 Million USD | 88.981% |